Overview

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Palbociclib
Tamoxifen